Telomir Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	3.44	2.37	0.02	0.01
Research & Development	1.94	1.57	0.83	0.13
Operating Expenses	5.38	3.94	0.85	0.14
Operating Income	-5.38	-3.94	-0.85	-0.14
Interest Expense	-5.98	-1.64	-	-
EBT Excluding Unusual Items	-11.36	-5.59	-0.85	-0.14
Other Unusual Items	-7.49	-7.49	-	-
Pretax Income	-18.84	-13.07	-0.85	-0.14
Net Income	-18.84	-13.07	-0.85	-0.14
Net Income to Common	-18.84	-13.07	-0.85	-0.14
Shares Outstanding (Basic)	28	27	27	-
Shares Outstanding (Diluted)	28	27	27	-
Shares Change (YoY)	2.34%	1.77%	-	-
EPS (Basic)	-0.68	-0.48	-0.03	-
EPS (Diluted)	-0.68	-0.48	-0.03	-
Free Cash Flow	-5.06	-3.86	-0.47	-0.12
Free Cash Flow Per Share	-0.18	-0.14	-0.02	-
EBIT	-5.38	-3.94	-0.85	-0.14

Source: S&P Capital IQ. Standard template.